Hong Kong Healthtech Stock News

AIA Group (SEHK:1299) has drawn investor attention after recent share price moves, with the stock showing mixed returns over the past month and past 3 months, alongside reported revenue of $26,215m and net income of $6,234m. See our latest analysis for AIA Group. Over the past year, AIA Group’s share price return has been more muted than its 47.66% total shareholder return. This suggests dividends and other distributions have played a meaningful role even as recent short-term share price...

AsiaInfo Technologies Limited's ( HKG:1675 ) earnings announcement last week didn't impress shareholders. Despite the...

As you might know, Jiumaojiu International Holdings Limited ( HKG:9922 ) last week released its latest annual, and...

NagaCorp Ltd. recently reported full-year 2025 results, with revenue of US$709.67 million and net income of US$309.91 million, and proposed a final dividend of US$0.0109 per share subject to shareholder approval on 25 June 2026. The combination of higher earnings per share of US$0.0701 and a new final dividend proposal signals management’s confidence in the company’s financial position. With these results and the proposed final dividend under consideration, we’ll explore how this payout...

China Conch Venture Holdings (SEHK:586) has come into focus after releasing its full year 2025 results, reporting sales of CN¥6,547.71 million and net income of CN¥2,245.14 million, alongside higher basic earnings per share. See our latest analysis for China Conch Venture Holdings. The latest full year earnings release has arrived alongside a shifting share price picture, with the stock at HK$11.95 after a 1 day share price return of 2.14% and a 7 day share price return of 8.64%. While the 90...

Why Simcere’s latest earnings and cancer trial update matter for investors Simcere Pharmaceutical Group (SEHK:2096) has just paired strong full year 2025 earnings with encouraging Phase I/II data for its bladder cancer therapy SIM0237, a combination that is drawing fresh attention from investors. See our latest analysis for Simcere Pharmaceutical Group. The latest 7.96% 1 day share price return to HK$12.07, alongside a 52.80% 1 year total shareholder return and solid multi year gains, points...

China Resources Gas Group (SEHK:1193) released its full year 2025 results, reporting sales of HK$97,732.61 million and net income of HK$3,546.79 million, both lower than the previous year, which helps frame the current focus of investors. See our latest analysis for China Resources Gas Group. The recent full year results, which showed lower sales and net income, appear to sit alongside weaker momentum in the share price. The 90 day share price return shows a decline of 16%, and the 1 year...

Amidst the backdrop of geopolitical tensions in the Middle East and fluctuating energy prices, Asian markets are navigating a complex landscape that influences investor sentiment across various sectors. As investors seek opportunities within this environment, penny stocks—though often considered niche—continue to attract attention for their potential to offer growth at a lower entry cost. These stocks, typically representing smaller or newer companies, can present significant value when...

As geopolitical tensions in the Middle East and volatile energy prices continue to influence global markets, Asian equities have been impacted by these developments, with investors closely watching how economies in the region navigate rising inflationary pressures. In this context, dividend stocks can offer a measure of stability and income potential, making them an attractive option for those looking to weather uncertain times while benefiting from consistent payouts.

Debt repurchase prompts fresh look at China Water Affairs Group China Water Affairs Group (SEHK:855) has repurchased and cancelled US$25,000,000 of its outstanding notes, about 7.1% of the original issue. This trims the remaining balance to US$325,000,000. See our latest analysis for China Water Affairs Group. The HK$4.94 share price has recently seen a 1.65% 1 day gain, but this follows a 6.44% year to date share price decline and a 22.04% 1 year total shareholder return decline, suggesting...

Why SY Holdings Group (SEHK:6069) is Back on Investors’ Radar SY Holdings Group (SEHK:6069) has drawn fresh attention after its 2025 earnings showed higher net income alongside slightly lower revenue, paired with a special dividend and a recommended increase in the final cash dividend. See our latest analysis for SY Holdings Group. Despite the latest earnings and dividend announcements, the 7 day share price return of a 10.0% decline and the 30 day share price return of a 13.48% decline at...

Why Country Garden Services Holdings is back in focus Country Garden Services Holdings (SEHK:6098) has drawn fresh attention after reporting full year 2025 results, which showed higher sales but a sharp drop in net income, alongside the completion of a sizeable share buyback program. See our latest analysis for Country Garden Services Holdings. The share price reaction has been mixed, with a 3.32% 1 day share price return and a 1.54% 7 day share price return, set against a 6.33% 30 day share...

United Company RUSAL International (SEHK:486) has released its full year 2025 results, reporting sales of US$14.8b and a net loss of US$455 million, a clear change from the prior year’s profit. See our latest analysis for United Company RUSAL International. The earnings release and upcoming board meeting on March 20 come against a weak backdrop, with a 30 day share price return of a 23.08% decline and a year to date share price return of a 15.11% decline, while the 3 year total shareholder...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Everest Medicines Limited recently reported full-year 2025 results, with sales of CNY 1,706.68 million versus CNY 706.68 million a year earlier and a net loss of CNY 297.77 million compared with CNY 1,041.38 million, alongside presentations at the American College of Cardiology 75th Annual Scientific Session in New Orleans in March 2026. The sharp increase in revenue and much smaller loss per share point to materially improved operating efficiency that could reshape how investors view the...

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just received Chinese regulator approval for its SKB103 IND in advanced solid tumors, marking a new clinical milestone that comes alongside recent earnings and oncology trial updates. See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical. The regulatory green light for SKB103 comes after a series of oncology updates and full-year 2025 results. The share price has reacted, with a 7.07% 1-day share price return and 18.12% 30-day...

Wynn Macau (SEHK:1128) has drawn fresh attention after releasing full year 2025 results that show revenue broadly steady while net income declined, alongside a higher recommended final ordinary dividend. See our latest analysis for Wynn Macau. The full year results and higher proposed dividend come after a mixed share price run, with a 7 day share price return of 4.50%, a 90 day share price return of 6.86% and a year to date share price return of 7.17%, while the 1 year total shareholder...

Looking at MicroPort Scientific Corporation's ( HKG:853 ) insider transactions over the last year, we can see that...

Shareholders appeared unconcerned with China Petroleum & Chemical Corporation's ( HKG:386 ) lackluster earnings report...

The subdued stock price reaction suggests that Besunyen Holdings Company Limited's ( HKG:926 ) strong earnings didn't...

Cryofocus Medtech (Shanghai) (SEHK:6922) has just posted its FY 2025 first half results, with revenue of ¥51.1 million and a basic EPS loss of ¥0.10, while trailing 12 month figures show revenue of ¥95.3 million and a basic EPS loss of ¥0.16. The company has seen revenue move from ¥19.5 million in the first half of FY 2024 to ¥34.1 million in the second half and then to ¥51.1 million in the first half of FY 2025, alongside net income losses of ¥52.2 million, ¥52.2 million and ¥23.8 million...

Changjiu Holdings (SEHK:6959) has just released its FY 2025 numbers, with first half revenue of C¥696.7 million and basic EPS of C¥0.33. This sets the stage against a trailing 12 month line that shows C¥1.62 billion in revenue and EPS of C¥0.70. Over recent reporting periods, revenue has moved from C¥337.2 million and EPS of C¥0.29 in 1H FY 2024, to C¥340.4 million and EPS of C¥0.51 in 2H FY 2024, before reaching the latest 1H FY 2025 levels. This leaves investors to weigh this earnings...

Dongguan Rural Commercial Bank (SEHK:9889) has wrapped up FY 2025 with fourth quarter revenue of C¥1.4b and net income of C¥209.3m, alongside trailing twelve month EPS of C¥0.56 on revenue of C¥8.3b. Over recent periods, revenue has ranged from C¥2.5b in the first quarter of 2025 to C¥1.4b in the fourth quarter, with quarterly net income moving between C¥1.6b and C¥209.3m, and trailing net profit margin easing from 52.4% to 46.4% over the last year. This puts the focus squarely on how...

Deewin Tianxia (SEHK:2418) has released its FY 2025 figures, reporting first half revenue of about CN¥1.1b and basic EPS of CN¥0.04. This is set against a trailing 12‑month picture where EPS is CN¥0.03 on revenue of roughly CN¥2.8b and net income of CN¥68.3m. Over recent periods the company’s revenue has moved from about CN¥1.3b in 1H 2024 to CN¥1.3b in 2H 2024, and then to roughly CN¥1.1b in 1H 2025. Basic EPS shifted from CN¥0.05 in 1H 2024 to CN¥0.02 in 2H 2024, and then to CN¥0.04 in 1H...